|Title of PI||Donepezil and memantine in moderate to severe Alzheimer’s disease – The DOMINO-AD Trial|
|Professor||Robert||Howard||King’s College London||UK|
|Institution||King’s College London|
- United Kingdom
Medical Research Council
- Alzheimer’s disease and other dementias
This RCT will examine efficacy of drug treatments for dementia (cholinesterase inhibitors and memantine), singly and in combination, over 12 months, in 800 Alzheimer s disease (AD)patients who are already treated with a cholinesterase inhibitor but have declined to reach the transition point to moderate to severe disease. Primary outcome measures will be cognitive function, activities of daily living and cost effectiveness. Secondary outcome measures will include quality of life, institutionalisation and family carer burden. The Trial has been designed to answer questions about the treatment of patients who are representative of those seen in clinical practice in terms of outcomes that have relevance to patients, carers and society.
- Clinical research